Answers are grounded in this paper and cite their sources.
We would like to document successful vedolizumab treatment in a 33-year-old man with anti-tumour necrosis factor [TNF]-refractory chronic pouchitis and concomitant primary sclerosing cholangitis [PSC]. The patient had been diagnosed with ulcerative colitis [UC] and PSC in 2011 and, due to the unresponsiveness to medical management, he underwent restorative proctocolectomy with ileo-anal pouch anastomosis between 2013 and 2014. As soon as 3 months after ileostomy closure, chronic pouchitis occurred, refractory to antibiotics and anti-TNF. Thus, vedolizumab was started in June 2016, leading to a marked improvement in clinical symptoms, which was maintained up at the end of follow-up [Week 34]. Compared with baseline [T = 0], Week 14 endoscopy [T = 1] documented complete resolution of erosions and ulcerations and reduced histological inflammation [Figure 1A]. Importantly, no treatment-related side effects, including no worsening of liver tests, were observed. The patient is currently under successful maintenance therapy with vedolizumab every 8 weeks. Endoscopic, histological and immunomodulatory effects of vedolizumab treatment at Week 0 [T = 0] and Week 14 [T = 1]. A] Endoscopic and histological images. B] Surface expression and frequencies of the α4β7 integrin on gated memory and Treg cells. C] Surface expression and frequencies of the α4β7 integrin on gated Th1, Th1/17, and Th17 cells. D] Histogram showing surface expression levels of CCR9 on gated memory and Treg cells. E] Histogram showing CCR9 expression on gated Th1, Th1/17, and Th17 cells. Immunomodulatory effect of vedolizumab treatment at Weeks 0 and 14 were analysed. Vedolizumab did not alter the percentages of peripheral α4β7+ memory or regulatory CD4+ T cells [Figure 1B]. Conversely, among CD4+ memory T-cell subsets, a selective increase of circulating α4β7+ memory Th17 and Th1/17 cells, which play a prominent role in intestinal inflammation,1 was observed after vedolizumab treatment [Figure 1C], a finding consistent with a blockade of their migration in the gut. Importantly, vedolizumab treatment was associated with increased circulating percentages of both memory and regulatory CD4+ T cells expressing CCR9 [Figure 1D], a surface marker implicated in migration of lymphocytes in the terminal ileum. Specifically, increased rates of circulating CCR9+ memory Th17 and Th1/17 cells were observed [Figure 1E]. In active pouchitis, the histological picture is dominated by a severe infiltration of the mucosa by both innate and adaptive immune cells. An increased proportion of mucosal dendritic cells expressing integrin β7 has been recently reported in patients with pouch inflammation in comparison with those with a normal pouch,2 to suggest a possible role of integrin signalling in the pathogenesis of this clinical condition. Blockade of α4β7 integrin with vedolizumab treatment might represent a promising therapeutic strategy for this clinical condition, implying that active homing of inflammatory cells in the pouch mucosa may be implicated in the disease pathogenesis. This work was supported by internal academic funding. None. The authors’ responsibilities were as follows: MC, MP, and FC designed research; MC and FC conducted research and followed up the patient; MP analysed samples and created figures; MC, MP, and FC wrote the paper. All authors read and approved the final manuscript.
No takes yet. Share an insight, caveat, or question.
Coletta et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: